U.K. Preparing COVID-19 Vaccine Trials That Deliberately Infect Study Subjects

A syringe at the Royal Free Hospital, north London, shown as part of a vaccine trial. Kirsty O’Connor – PA Images/PA Images via Getty Images hide caption

toggle caption

Kirsty O’Connor – PA Images/PA Images via Getty Images

Researchers in Britain are preparing to start a controversial COVID-19 “human challenge” study in which dozens of healthy volunteers will be exposed to live coronavirus in an effort to speed up vaccine development.

The Human Challenge Programme will be conducted by Imperial College London, which said Tuesday in a statement that it would be working in cooperation with the Department for Business, Energy and Industrial Strategy, the Royal Free London NHS Foundation Trust, and hVIVO, a clinical company that has worked on viral human challenge models.

The U.K. government is preparing to invest $43.4 million (33.6 million pounds) in the study.

The study, the first of its kind involving the coronavirus, will recruit healthy people between the ages of 18 and 30 with no prior history of COVID-19 symptoms and no known risk factors for the disease. Researchers would inoculate them with a candidate vaccine, then test its effectiveness by deliberately exposing them to live coronavirus.

Such studies are controversial because they raise ethical concerns. However, proponents say they can speed up vaccine development and, ultimately, save lives.

“No study is completely risk free, but the Human Challenge Program partners will be working hard to ensure we make the risks as low as we possibly can,” lead researcher Dr. Chris Chiu from Imperial College London said in the statement.

“The UK’s experience and expertise in human challenge trials as well as in wider COVID-19 science will help us tackle the pandemic, benefiting people in the UK and worldwide,” he said.

“Participants in the initial study will be carefully selected to exclude anyone with a characteristic that has been shown to increase the severity of COVID-19 infection,” hVIVO said in a statement.

Similar trials are being investigated in Belgium. The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is funding the development of two SARS-CoV-2 challenge strains at a lab at Colorado State University in Fort Collins, according to Nature, and NIAID is reportedly awaiting data from phase III vaccine studies before making decisions on COVID-19 challenge trials.

In the first part of the U.K. study, researchers will try to determine the smallest amount of virus required for a person to develop COVID-19 and illicit an immune response. That phase is scheduled to be wrap up sometime next year.

“The proportion of participants becoming infected and the amount of virus that they subsequently shed will be tracked to better understand the course of infection,” Imperial College London said in the statement.

Vaccine taskforce chair Kate Bingham said the research will boost knowledge of the virus and aid further research.

“There is much we can learn in terms of immunity, the length of vaccine protection, and reinfection,” she said in a statement, according to The Associated Press.

A non-profit group called 1Day Sooner has already attracted more than 38,500 volunteers in more than 165 countries to take part in such studies.

“I would be lying if I said there’s not like an underlying worry there or fear there because this virus is less than a year old,” Chris Holdsworth, 25, who is studying for a PhD at the University of Edinburgh and says he would be willing to participate, told The Guardian. “But at the same time I just try to contextualise the risk, without trivialising it.”

Scott Neuman
Author: Scott Neuman

This post was originally published on this site

Leave a Comment